Skye Bioscience to Announce Third Quarter 2024 Results
Skye Bioscience (Nasdaq: SKYE) has scheduled the release of its third quarter 2024 financial results for Thursday, November 7, 2024, after market close. The clinical-stage biopharmaceutical company, which focuses on metabolic health therapeutics, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. Investors can access the live webcast, earnings release, financial tables, and presentation through Skye's Investor Relations website, where a replay and transcript will be available afterward.
Skye Bioscience (Nasdaq: SKYE) ha programmato la pubblicazione dei suoi risultati finanziari del terzo trimestre 2024 per giovedì 7 novembre 2024, dopo la chiusura del mercato. La società biofarmaceutica in fase clinica, che si concentra sulla salute metabolica terapeutica, organizzerà una conferenza telefonica alle 13:30 PT/16:30 ET per discutere i risultati. Gli investitori possono accedere al webcast dal vivo, al comunicato sugli utili, alle tabelle finanziarie e alla presentazione attraverso il sito web delle Relazioni con gli Investitori di Skye, dove una registrazione e un trascritto saranno disponibili successivamente.
Skye Bioscience (Nasdaq: SKYE) ha programado la publicación de sus resultados financieros del tercer trimestre de 2024 para el jueves 7 de noviembre de 2024, después del cierre del mercado. La compañía biofarmacéutica en etapa clínica, que se enfoca en terapias de salud metabólica, llevará a cabo una llamada de conferencia a la 1:30 p.m. PT/4:30 p.m. ET para discutir los resultados. Los inversores pueden acceder a la transmisión en vivo, al comunicado de ganancias, a las tablas financieras y a la presentación a través del sitio web de Relaciones con Inversores de Skye, donde estará disponible una grabación y una transcripción posteriormente.
스카이 바이오사이언스 (Nasdaq: SKYE)는 2024년 11월 7일 목요일 시장 마감 후 2024년 3분기 재무 결과 발표를 예정하고 있습니다. 대사 건강 치료제에 집중하는 임상 단계의 생물 제약 회사는 결과를 논의하기 위해 오후 1시 30분 PT/오후 4시 30분 ET에 컨퍼런스 콜을 개최할 예정입니다. 투자자들은 스카이의 투자자 관계 웹사이트를 통해 생중계, 수익 발표, 재무 표 및 프레젠테이션에 접속할 수 있으며, 이후에 다시보기와 전사본도 제공될 예정입니다.
Skye Bioscience (Nasdaq: SKYE) a prévu la publication de ses résultats financiers du troisième trimestre 2024 pour le jeudi 7 novembre 2024, après la clôture du marché. L'entreprise bio-pharmaceutique en phase clinique, qui se concentre sur les thérapies de santé métabolique, organisera une conférence téléphonique à 13h30 PT/16h30 ET pour discuter des résultats. Les investisseurs peuvent accéder au webinaire en direct, au communiqué de résultats, aux tableaux financiers et à la présentation via le site des relations investisseurs de Skye, où une rediffusion et une transcription seront disponibles par la suite.
Skye Bioscience (Nasdaq: SKYE) hat die Veröffentlichung ihrer finanziellen Ergebnisse für das dritte Quartal 2024 für Donnerstag, den 7. November 2024, nach Marktschluss angesetzt. Das klinische biopharmazeutische Unternehmen, das sich auf Therapien für die metabolische Gesundheit konzentriert, wird um 13:30 Uhr PT/16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu diskutieren. Investoren können über die Investor-Relations-Website von Skye auf den Live-Webcast, die Gewinnmitteilung, die finanziellen Tabellen und die Präsentation zugreifen, wo auch eine Aufzeichnung und ein Transkript verfügbar sein werden.
- None.
- None.
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that the company's third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024. Skye will host a conference call to discuss its results at 1:30 p.m. PT/4:30 p.m. ET.
The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Following the call, a replay and transcript will be available at the same website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. These forward looking statements include, but are not limited to: statements regarding our product development, statements regarding the ability of nimacimab to treat obesity or related indications, and statements regarding the therapeutic potential of nimacimab. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
FAQ
When will Skye Bioscience (SKYE) release Q3 2024 earnings?
What time is Skye Bioscience's (SKYE) Q3 2024 earnings call?
How can investors access Skye Bioscience's (SKYE) Q3 2024 earnings call?
